Virtus LifeSci Biotech Products ETF (NYSEARCA:BBP – Get Free Report) was the target of a large decline in short interest in September. As of September 15th, there was short interest totaling 3,321 shares, a decline of 87.9% from the August 31st total of 27,525 shares. Currently, 0.3% of the shares of the stock are sold short. Based on an average daily trading volume, of 8,922 shares, the days-to-cover ratio is currently 0.4 days.
Hedge Funds Weigh In On Virtus LifeSci Biotech Products ETF
A hedge fund recently bought a new position in Virtus LifeSci Biotech Products ETF stock. Comprehensive Financial Planning Inc. PA acquired a new position in shares of Virtus LifeSci Biotech Products ETF (NYSEARCA:BBP – Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 6,971 shares of the company’s stock, valued at approximately $557,000. Comprehensive Financial Planning Inc. PA owned approximately 1.27% of Virtus LifeSci Biotech Products ETF at the end of the most recent quarter.
Virtus LifeSci Biotech Products ETF Stock Performance
Virtus LifeSci Biotech Products ETF stock traded down $0.06 during mid-day trading on Friday, hitting $104.57. 5,367 shares of the company were exchanged, compared to its average volume of 8,708. The business has a fifty day moving average of $102.66 and a 200 day moving average of $92.95. Virtus LifeSci Biotech Products ETF has a 1-year low of $68.05 and a 1-year high of $110.05.
About Virtus LifeSci Biotech Products ETF
The Virtus LifeSci Biotech Products ETF (BBP) is an exchange-traded fund that is based on the LifeSci Biotechnology Products index. The fund tracks an index of US-listed biotechnology companies considered to be in the product stage by the index provider. BBP was launched on Dec 17, 2014 and is managed by Virtus.
Recommended Stories
- Five stocks we like better than Virtus LifeSci Biotech Products ETF
- Costco Ends Its Fiscal Year on a High Note, Eyes Big Expansion
- Cracker Barrel Stock Is Rallying Again, But the Turnaround Still Has a Traffic Problem
- Oracle’s Force Majeure Notice Exposes a Bigger Problem for the AI Build-Out
- Oil May Be Stronger Than It Looks—And Diamondback Is on Sale
Receive News & Ratings for Virtus LifeSci Biotech Products ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Virtus LifeSci Biotech Products ETF and related companies with MarketBeat.com's FREE daily email newsletter.
